Feed Antibiotics - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The feed antibiotics market size is projected to grow from USD 3.85 billion in 2025 to USD 3.99 billion in 2026, reaching USD 4.79 billion by 2031, with a CAGR of 3.7% during the 2026-2031 period. This report is Segmented by Type (Tetracyclines, Penicillin, Sulfonamides, Macrolides, Aminoglycosides, Cephalosporins, and Others), by Animal Type (Ruminant, Poultry, Swine, Aquaculture, and Others), and by Geography (North America, Europe, Asia-Pacific, South America, Middle-East and Africa). The Market Size and Growth Forecasts are Provided in Terms of Value (USD).

Global Feed Antibiotics Market Trends and Insights

Rising Poultry and Swine Production Increases Medicated Feed Demand

Disease dynamics in dense production environments necessitate targeted therapeutic use under veterinary supervision, guided by surveillance data and prescribed durations of use . Positivity rates for porcine reproductive and respiratory syndrome increased in 2025, indicating ongoing respiratory challenges that heighten the need for treatment during swine finishing and nursery phases . In large broiler complexes and integrated pork operations, standardized protocols for diagnosis, dosing, and withdrawal periods are integral to production risk management. Producers are adapting by integrating biosecurity measures, vaccination, and time-limited therapies, monitored through mill-veterinarian systems and audited process controls.

Compound Feed Growth Supports Antibiotic Volumes

The growth of compound feed production in key livestock economies continues to support the use of feed-based antibiotic delivery for approved therapeutic purposes. According to the Alltech Global Feed Survey, global compound feed production exceeded 1.39 billion metric tons in 2024, indicating consistent growth in livestock production systems. In China, compound feed production surpassed 315 million metric tons in 2024, as reported by the China Feed Industry Association. This growth has been driven by government efforts to modernize feed mills and enhance quality control measures, ensuring accurate dosing and improved traceability in medicated feed.

Phase-Out of Growth Promoters Limits Usage

Regulatory authorities in key markets have implemented measures to prohibit the non-therapeutic use of antibiotics for growth promotion, while allowing their use for treatment, control, and prevention under specific conditions. In China, the Ministry of Agriculture and Rural Affairs has established policies banning antibiotic growth promoters and mandating veterinary oversight for therapeutic applications. Similarly, in North America, prescription requirements and Veterinary Feed Directive regulations have reclassified antibiotics as a supervised resource rather than a routine input, with clear guidelines on their duration and indications.

Other drivers and restraints analyzed in the detailed report include:

• Cost-Effective Tetracyclines Remain Widely Used
• Veterinary Oversight Improves Compliance
• Demand for Antibiotic-Free Products Shifts Preferences

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

Tetracyclines accounted for the largest 65.0% of the global feed antibiotics market share in 2025, while the global feed antibiotics market size for macrolides is projected to achieve the fastest segment growth with a 3.8% CAGR from 2026 to 2031, highlighting their distinct roles in managing respiratory and enteric disease complexes. In the United States, tetracyclines held the largest share of medically important antimicrobial sales for food-producing animals in 2024, emphasizing their role in cost-effective therapy with established withdrawal schedules. Pleuromutilins continue to gain traction in swine, driven by established products and ongoing label expansions that enhance their clinical utility for mycoplasma and respiratory pathogens .

Ionophores, which are not classified as medically important for human medicine, remain widely utilized in poultry coccidiosis programs and support feed-conversion control strategies under specific regulatory frameworks. Within the broader therapeutic landscape, aminoglycosides, sulfonamides, and penicillins address specific indications based on pathogen profiles and farm-stage requirements, with veterinarians tailoring treatments to disease pressures and documented susceptibilities. Looking ahead, the feed antibiotics market is projected to see increased use of macrolides in targeted applications, where label convenience and defined durations align with oversight and labor constraints.

Complete Report Scope:

• By Type
  • Tetracyclines
  • Penicillins
  • Sulfonamides
  • Macrolides
  • Aminoglycosides
  • Cephalosporins
  • Other types
• By Animal Type
  • Ruminant
  • Poultry
  • Swine
  • Aquaculture
  • Other animal types
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
    • Rest of North America
  • Europe
    • Spain
    • United Kingdom
    • Germany
    • France
    • Russia
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • Thailand
    • Australia
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Middle East
    • Saudi Arabia
    • Turkey
    • Rest of Middle East
  • Africa
    • South Africa
    • Egypt
    • Rest of Africa

Geography Analysis

Asia-Pacific accounted for the largest 35.0% of the feed antibiotics market share in 2025, and the feed antibiotics market size for Asia-Pacific is projected to grow at the fastest CAGR of 4.2% from 2026 to 2031. This growth reflects the region's significant poultry and swine production, ongoing modernization of feed mills, and veterinary oversight for therapeutic applications. According to the United States Department of Agriculture, poultry production is projected to reach approximately 15.8 million metric tons in 2026, with growth driven by white-broiler production. White-broiler systems account for nearly 70% of total output, supported by vertically integrated operations that dominate industrial poultry production.

North America is driven by formal oversight frameworks and disease management needs, particularly in cattle and swine. The 2026 duration-of-use initiative enhances label clarity for selected in-feed approvals, reducing historical ambiguity around continuous use and aiding planning for feedlots and large integrators. In 2024, United States sales data indicated a significant share held by tetracyclines among medically important antibiotics, reflecting their widespread utility and cost-effectiveness for respiratory and enteric conditions. Swine health surveillance in 2025 recorded elevated numbers of cases of porcine reproductive and respiratory syndrome, underscoring the ongoing demand for supervised therapy at finishing and nursery sites.

Europe is shaped by the region's long-standing prohibition on antibiotic growth promoters and its emphasis on veterinary oversight for therapeutic use. National regulators collaborate with international standards bodies to enhance medicine governance, promoting improved stewardship and residue control in feed-based therapies. Producers in Europe continue to invest in vaccination, enzymes, and phytogenics while maintaining access to in-feed antibiotics for labeled indications under veterinary supervision. As supply chains expand antibiotic-free offerings, processors and retailers demand more rigorous compliance evidence, increasing documentation requirements for feed mills and farms.

List of Companies Covered in this Report:

• Bayer AG
• Merck & Co., Inc.
• Zomedica Corp.
• Elanco Animal Health Incorporated
• Phibro Animal Health Corporation
• Huvepharma EOOD
• Sanofi-Aventis Societe Anonyme
• LG Chem Ltd.
• American Regent, Inc.
• ECO Animal Health Group plc
• Zoetis Inc.
• Alpha-Vet Animal Health Kft.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support